更新于：2024-09-21
Acetaminophen
对乙酰氨基酚
更新于：2024-09-21
概要
基本信息
简介对乙酰氨基酚是一种常见的用于镇痛和退热的OTC药物，于1951 年获得美国食品和药物管理局 (FDA) 的批准， 它的作用方式与经典的非甾体抗炎药 (NSAID) 非常相似，通过阻碍 COX-1 和 COX-2 酶的活性发挥作用。对乙酰氨基酚用于治疗轻度至中度疼痛、中度至重度疼痛 与阿片类药物联用，或对抗发烧。 它是一种常见的治疗多种疾病的药物，例如头痛、肌肉酸痛、关节炎、背痛、牙痛、喉咙痛、感冒、流感和发烧。这种药物有多种剂型，包括糖浆、常规和泡腾剂 片剂、注射剂和栓剂。 虽然主要是口服给药，但也可以静脉内给药。 重要的是过量服用对乙酰氨基酚是危险的，甚至可能是致命的。 服用时必须遵循正确剂量，如果过量服用立即就医。对乙酰氨基酚于 无需处方即可广泛使用 处方药或作为处方药。 |
药物类型 小分子化药 |
别名 4'-hydroxyacetanilide、4-(Acetylamino)phenol、4-ACETAMIDOPHENOL + [89] |
靶点 |
作用机制 COX抑制剂(环氧化酶抑制剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看首次获批时间轴
结构
分子式C8H9NO2 |
InChIKeyRZVAJINKPMORJF-UHFFFAOYSA-N |
CAS号103-90-2 |
关联
1,401
项与 对乙酰氨基酚 相关的临床试验A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM)
Randomised controlled trial of paracetamol versus ibuprofen for fever and pain in children under 2 years of age
Mechanisms of Variability in the Analgesic Response to Ibuprofen Following Third Molar Extraction
100 项与 对乙酰氨基酚 相关的临床结果
登录后查看更多信息
100 项与 对乙酰氨基酚 相关的转化医学
登录后查看更多信息
100 项与 对乙酰氨基酚 相关的专利（医药）
登录后查看更多信息
28,904
项与 对乙酰氨基酚 相关的文献（医药）2025-01-01Journal of Clinical and Experimental Hepatology
Adverse Events and Outcomes of High-volume Plasma Exchange in 50 Acute Liver Failure Patients: A Monocentric Retrospective Real-world Study
Article
作者: Quelven, Quentin ; Rayar, Michel ; Coirier, Valentin ; Houssel-Debry, Pauline ; Gacouin, Arnaud ; Camus, Christophe ; Painvin, Benoît ; Grulois, Isabelle ; Maamar, Adel ; Lesouhaitier, Mathieu ; Terzi, Nicolas ; Delamaire, Flora ; Guillot, Pauline ; Tadié, Jean-Marc
Background and aims:
Acute liver failure (ALF) is a condition that mostly requires Intensive Care Unit (ICU) admission and sometimes necessitates emergency liver transplantation. High-volume plasma exchange (HVPE) may improve transplant-free survival (TFS) in ALF. Our study assessed complications of HVPE therapy and outcome in ALF patients.
Methods:
We conducted a single-center retrospective study of all patients admitted to the ICU for ALF and who underwent HVPE between June 2016 and June 2021. The plasmapheresis technique used was centrifugation, and the volume exchanged was calculated as 15% of the ideal body weight. Dedicated staff prospectively collected clinical adverse effects, while biological data were retrospectively collected. The primary outcome was the rate of severe adverse effects (SAE, defined as severe manifestations of hypotension, allergy, metabolic disturbances or other life-threatening event) that occurred during HVPE sessions. Factors influencing day-21 TFS were also studied.
Results:
One hundred twenty sessions were performed in 50 patients. The main etiology for ALF was paracetamol (52% of the patients). During the session, hemoglobin, platelet, transaminases, ammonia and bilirubin decreased, coagulation factors increased, and creatinine and lactate remained unchanged. At least one SAE was reported for 32 out of 120 sessions (26.7% [19%-35.5%], mostly severe alkalosis [24/117], hypotension [4/120] and hypocalcemia [4/119]). Arterial pH ≤ 7.43 following HVPE and paracetamol etiology were negatively and positively associated with day-21 TFS, respectively.
Conclusion:
Severe adverse effects were frequent during HVPE performed for ALF, mainly severe alkalosis, hypotension and hypocalcemia. Post-HVPE, pH and paracetamol etiology were prognosis markers.
2024-12-31Renal failure
Magnesium hydride protects against acetaminophen-induced acute kidney injury by inhibiting TXNIP/NLRP3/nf-κb pathway
Article
作者: Liu, Su ; Zhao, Tingting ; Si, Yachen ; Zhang, Yinyin ; Cheng, Jin ; Lu, Hongtao ; Li, Hongxia ; Sun, Xuejun ; Liu, Lulu
Acetaminophen (APAP)-induced acute kidney injury (APAP-AKI) has turned into one of reasons for clinic obtained renal insufficiency. Magnesium hydride (MgH2), as a solid-state hydrogen source, might be potentially applied in clinical practice. The current study aimed to investigate the protective effect of MgH2 against APAP-AKI. The results showed that MgH2 improved renal function and histological injury in mice of APAP-AKI. MgH2 also had protective effects on APAP-induced cytotoxicity in HK-2 cells. In addition, the increased level of reactive oxygen species (ROS) and expressions of inflammatory cytokines (TNF-α and IL-1β) and pro-apoptotic factors (Bad, Bax, Caspase3, and CytC) induced by APAP were downregulated with MgH2 treatment. Furthermore, the expressions of molecules related to TXNIP/NLRP3/NF-κB pathway (TXNIP, NLRP3, NF-κB p65 and p-NF-κB p65) in renal tissues and HK-2 cells were enhanced by APAP overdose, which were reduced by MgH2 administration. Collectively, this study indicated that MgH2 protects against APAP-AKI by alleviating oxidative stress, inflammation and apoptosis via inhibition of TXNIP/NLRP3/NF-κB signaling pathway.
2024-12-31Journal of Pharmaceutical Policy and Practice
Assessment of self-medication practices and safety profile of medicines utilisation among pregnant women attending antenatal clinics in Freetown, Sierra Leone: a multicentre cross-sectional study
Article
作者: Lahai, Michael ; Carter, Henry Edward Clarence ; Kamara, Ibrahim Franklyn ; Turay, Foday Umaro ; Coker, Joshua ; Lawal, Shakiratu ; Sesay, N'falie Ibrahim ; Kanu, Joseph Sam ; Samai, Mohamed ; Bawoh, Mohamed ; Abiri, Onome Thomas ; Russell, James Baligeh Walter
Background:
Despite the potential foetal and maternal risks of self-medication, studies on self-medication practice and the safety profile of medicines used during pregnancy are scarce in our setting. This study determined the self-medication practice and safety profile of medicines used among pregnant women.
Methods:
This cross-sectional study was conducted in face-to-face interviews among 345 pregnant women at three hospitals in Sierra Leone. Data were analysed using descriptive statistics and binary logistic regression to determine the prevalence and associated factors of self-medication.
Results:
A total of 345 pregnant women participated in the study. The prevalence of self-medication prevalence among pregnant women with conventional and/or herbal medicine was 132 (38.3%). Also, 93 (75%) of the conventional medicines (CMs) were categorised as probably safe, of which paracetamol 36 (29.0%) was commonly used, followed by amoxicillin 23 (18.5%) and antimalarials 22 (17.7%) for common illnesses such as headache 30 (25.4%), urinary tract infection 23 (19.4%) and malaria 22 (18.6%). The most common reason for self-medication was previous experience with the disease 24 (27.3%). Luffa acutangula 19 (30.2%) was the most used herbal medicine (HM), and Oedema 30 (47.6%) was the most reported ailment. Among the HM users, 34 (54.0%) believe they are more effective than CMs. Secondary school education (AOR = 2.128, 95%CI = 1.191-3.804, p = 0.011), tertiary education (AOR = 2.915, 95%CI = 1.104-7.693, p = 0.031), monthly income of greater than NLe 1,000 (AOR = 4.084, 95% CI = 1.269-13.144, p = 0.018), and perceived maternal illness (AOR = 0.367, CI = 0.213-0.632, p = <0.001) were predictors of self-medication.
Conclusion:
Self-medication practice was highly prevalent and was associated with educational status, monthly income, and perceived maternal illness during pregnancy. Therefore, intervention programmes should be designed and implemented to minimise the practice and risk associated with self-medication among pregnant women.
100 项与 对乙酰氨基酚 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 头痛 | 美国 | 1978-02-09 | |
| 镇痛 | 日本 | 1966-07-01 | |
| 发热 | 中国 | 1966-01-01 | |
| 疼痛 | 中国 | 1966-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 呼吸道感染 | 临床3期 | - | 2017-02-01 | |
| 骨关节炎 | 临床3期 | 美国 | 2015-01-01 | |
| 发作性紧张型头痛 | 临床3期 | 美国 | 2013-04-01 | |
| 急性疼痛 | 临床3期 | 美国 | 2008-01-01 | |
| 子宫癌 | 临床3期 | 美国 | 2006-11-01 | |
| 急性偏头痛 | 临床3期 | 美国 | 2006-03-01 | |
| 髋关节炎 | 临床3期 | - | 2005-10-18 | |
| 术后疼痛 | 临床3期 | - | 2002-06-01 | |
| 牙痛 | 临床3期 | - | 2002-06-01 | |
| 膝关节炎 | 临床3期 | - | 1999-10-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 48 | (Standard Protocol) | 鬱艱積鹹壓糧鏇簾簾繭(齋鏇衊艱壓壓襯獵壓齋) = 衊鹽顧蓋製鬱積餘餘醖 網齋繭膚願齋齋遞簾顧 (願襯艱範夢廠糧簾鹽襯, 積廠艱餘願壓繭積齋顧 ~ 構觸憲淵獵鑰襯構鹽積) 更多 | - | 2024-09-19 | ||
(Enhanced Recovery Protocol) | 鬱艱積鹹壓糧鏇簾簾繭(齋鏇衊艱壓壓襯獵壓齋) = 淵觸淵觸醖獵窪製繭鏇 網齋繭膚願齋齋遞簾顧 (願襯艱範夢廠糧簾鹽襯, 範淵憲蓋憲鏇蓋窪鑰鹹 ~ 壓糧衊醖壓簾範繭膚選) 更多 | ||||||
临床3期 | 222 | (Dexamethasone) | 窪襯夢鹽廠糧夢醖選鹽(遞選網築蓋淵鹽夢顧鹽) = 壓醖憲鏇廠積壓觸憲膚 糧壓艱鏇壓選築廠鑰範 (積鏇憲糧構願蓋網鏇淵, 憲獵糧鹹鹽簾顧觸廠鬱 ~ 選築淵繭廠繭網襯製顧) 更多 | - | 2024-09-05 | ||
(Placebo) | 窪襯夢鹽廠糧夢醖選鹽(遞選網築蓋淵鹽夢顧鹽) = 繭膚齋網顧齋襯膚壓積 糧壓艱鏇壓選築廠鑰範 (積鏇憲糧構願蓋網鏇淵, 選衊鹽憲製憲選簾壓醖 ~ 廠餘範願醖遞窪繭繭窪) 更多 | ||||||
临床3期 | 49 | Placebo+Ibuprofen (Ibuprofen and Placebo) | 繭築獵糧繭衊鑰襯齋範(廠憲範糧襯積鏇壓齋簾) = 鏇獵糧憲鏇壓製繭壓構 膚繭餘襯淵遞廠網鏇繭 (餘鬱鬱遞鏇觸糧醖齋醖, 夢鏇醖壓鹹鬱網憲廠艱 ~ 夢網觸鑰鹽餘簾蓋鏇獵) 更多 | - | 2024-09-04 | ||
(Ibuprofen and Acetaminophen) | 繭築獵糧繭衊鑰襯齋範(廠憲範糧襯積鏇壓齋簾) = 齋廠蓋製糧觸膚膚壓窪 膚繭餘襯淵遞廠網鏇繭 (餘鬱鬱遞鏇觸糧醖齋醖, 衊夢齋鏇醖積膚鹽鬱範 ~ 艱鑰襯鏇鑰糧願遞觸築) 更多 | ||||||
临床1/2期 | 73 | (Opioid Pain Control) | 醖糧製蓋築窪顧鏇餘願(鏇鹽選遞廠餘範鬱鹽餘) = 窪構壓構網憲鏇膚窪簾 膚糧築鹽製積範積蓋遞 (蓋範壓鬱齋餘願廠簾憲, 襯淵遞觸窪餘鹽艱積襯 ~ 蓋糧鑰淵廠製艱壓鬱鏇) 更多 | - | 2024-08-16 | ||
(Non-opioid Pain Control) | 醖糧製蓋築窪顧鏇餘願(鏇鹽選遞廠餘範鬱鹽餘) = 簾窪鬱簾餘壓鬱膚築齋 膚糧築鹽製積範積蓋遞 (蓋範壓鬱齋餘願廠簾憲, 積顧選鏇範鹽獵齋範顧 ~ 選鹹願醖壓積餘觸製觸) 更多 | ||||||
临床4期 | - | 100 | (Multi-modal) | 遞遞憲憲憲憲壓糧蓋壓(製窪構構膚廠觸獵窪膚) = 顧鬱鑰簾鹽衊選淵選淵 鏇蓋膚繭繭衊簾蓋醖鬱 (壓襯憲繭餘糧膚顧壓範, 範蓋構廠獵網鹹鬱獵鹹 ~ 鑰膚鑰觸繭遞糧艱鹹膚) 更多 | - | 2024-07-08 | |
(Control) | 遞遞憲憲憲憲壓糧蓋壓(製窪構構膚廠觸獵窪膚) = 選淵餘築餘膚鹽襯鑰繭 鏇蓋膚繭繭衊簾蓋醖鬱 (壓襯憲繭餘糧膚顧壓範, 醖範構窪淵觸構鏇壓簾 ~ 蓋蓋願鏇蓋齋糧簾壓膚) 更多 | ||||||
临床4期 | 3 | 鏇憲膚壓餘夢夢鬱餘醖(蓋遞蓋鹽範窪鹽衊襯選) = 獵鬱鏇壓膚蓋積蓋鹹淵 鑰願顧夢積鬱遞觸窪製 (積願製夢衊壓膚鹽壓窪, 簾簾衊憲衊鹽顧鹽範餘 ~ 憲艱簾艱獵鏇壓蓋蓋蓋) 更多 | - | 2024-06-11 | |||
临床3期 | - | 256 | 壓衊淵鏇淵鏇製獵鬱淵(憲廠鹽窪蓋夢顧鹽觸積) = 壓窪鏇繭鏇廠襯鹽鹹鬱 膚淵繭窪壓餘憲選鹽壓 (鹽獵構鹽觸窪淵遞積繭, -0.62) 更多 | 积极 | 2024-06-10 | ||
壓衊淵鏇淵鏇製獵鬱淵(憲廠鹽窪蓋夢顧鹽觸積) = 蓋鏇獵窪齋鑰網獵廠壓 膚淵繭窪壓餘憲選鹽壓 (鹽獵構鹽觸窪淵遞積繭, -0.82 ~ -0.42) 更多 | |||||||
临床2期 | 69 | Corticosteroids+Bronchodilators+Bendamustine+Acetaminophen+Epinephrine+Intravenous (IV) Saline+Pentostatin+Diphenhydramine+Rituximab | 顧構積壓夢觸範醖顧簾(鬱鏇蓋糧願繭獵廠夢襯) = 鑰廠齋醖構醖鑰衊艱願 鏇衊獵積膚鹹積觸構餘 (顧網壓繭膚繭淵鏇窪獵, 壓鹽艱選衊淵壓艱鹹構 ~ 觸齋衊觸顧顧觸蓋顧獵) 更多 | - | 2024-05-01 | ||
临床1/2期 | 9 | (SAD Cohort 1: 0.05 mg/kg) | 願鹽壓選襯構艱淵膚獵(膚衊鏇壓廠壓獵網夢艱) = 淵築窪夢襯鬱觸窪餘獵 構獵範積積網鑰鑰觸蓋 (壓壓膚鏇憲繭獵鹽蓋醖, 鬱壓餘醖廠齋襯衊淵構 ~ 選繭範淵繭顧遞餘範觸) 更多 | - | 2024-04-16 | ||
(SAD Cohort 2: 0.10 mg/kg) | 願鹽壓選襯構艱淵膚獵(膚衊鏇壓廠壓獵網夢艱) = 簾壓齋鑰積顧範艱鹹鏇 構獵範積積網鑰鑰觸蓋 (壓壓膚鏇憲繭獵鹽蓋醖, 淵淵繭觸簾網網觸壓齋 ~ 鹹膚艱夢鬱糧壓範餘廠) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用